Valion Bio

VBIO

Börsenwert 1,04 Mio. $

Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, viability, and phenotype within bioreactors Milestone achieved less than six months after Valion Bio secured exclusive rights to LarmorBio's next-generation NMR technology SAN ANTONIO, TX AND WALTHAM, MA / ACCESS Newswire / October 15, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization ("CDMO") subsidiary, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR™ platform. BioScan-NMR™ is being developed to create a new class of process analytical technology ("PAT") for biologics manufacturing.

Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production SAN ANTONIO, TX / ACCESS Newswire / October 14, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today highlighted the capabilities of its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks. Velocity Bioworks ("Velocity") is part of Valion's own domestic biologics supply chain, supporting the Company's development strategy for its lead candidate, Entolimod, which is being developed as a potential medical countermeasure for Acute Radiation Syndrome.

Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹ Medical countermeasures need to scale along with that infrastructure Valion is developing an oral mucosal formulation of Entolimod that could potentially provide a needle-free administration option for acute radiation syndrome ("ARS") SAN ANTONIO, TX / ACCESS Newswire / October 9, 2026 / As nuclear power assumes an increasingly important role in meeting the growing electricity requirements of artificial intelligence, data centers and other digital infrastructure, the expansion of the U.S. nuclear-energy landscape that has been increasingly making headlines across the country is also highlighting the importance of resilient emergency preparedness and medical countermeasures for potential radiological and nuclear events. Against this backdrop, Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection, believes the evolving U.S. nuclear energy landscape reinforces the importance of advancing medical countermeasures that could be deployed rapidly and at population scale in the event of a radiological or nuclear emergency.

Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing SAN ANTONIO, TX / ACCESS Newswire / October 5, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today outlined the perspectives of its new Board Chair, Thomas H. Jensen, on advancing Entolimod.

Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod program Next study will test whether the formulation delivers measurable amounts of Entolimod into the bloodstream SAN ANTONIO, TX / ACCESS Newswire / September 30, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and Shear Kershman Laboratories ("SKL") today announced the successful completion of formulation work under the companies' ongoing program to develop a novel oral mucosal formulation of Entolimod*, Valion's investigational biologic aimed at protecting cells from severe damage or death from radiation exposure, using SKL's proprietary BioViscid™ drug-delivery platform. The milestone advances a potential second delivery pathway for Entolimod, which has historically been administered by injection.

Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the "Board"). These leadership transitions are intended to strengthen organizational alignment and support focused execution as Valion advances its Entolimod and other development programs and evaluates strategic opportunities.

Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company) announced today that it has received formal written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $1.00 per share.

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.

SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").

Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement Formal review accepted July 22 • Ministry begins technical assessment • Regulatory requirements defined • Potential decision as early as Q4 2026 Near-Term Regulatory Catalyst Formal review underway: Ukraine's Ministry of Health accepted the Entolimod dossier for formal review on July 22, 2026. Technical assessment underway: Ukraine's Ministry of Health has begun technical assessment of the dossier and issued its first round of questions, relating to the physicochemical characterization of the drug product that would be supplied under a potential stockpiling arrangement.